Bio-Rad Laboratories’s Earnings: A Preview

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2022-02-10. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad Laboratories will likely report an Earnings Per Share (EPS) of $2.85.

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2022-02-10. Here’s what investors need to know before the announcement.

Analysts estimate that Bio-Rad Laboratories will likely report an Earnings Per Share (EPS) of $2.85.

Bio-Rad Laboratories bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $1.27, which was followed by a 0.74% increase in the share price the next day.

Here’s a look at Bio-Rad Laboratories’s past performance and the resulting price change:

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate 2.44 2.66 3 3.29
EPS Actual 3.71 3.54 5.21 4.01
Price Change % 0.74% 4.58% -1.65% 2.88%

eps graph

Stock Performance

Shares of Bio-Rad Laboratories were trading at $617.6 as of February 08. Over the last 52-week period, shares are down 2.14%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

If you want to track all upcoming earnings announcements, check out our Earnings Calendar here

Total
0
Shares
Related Posts
Read More

Procaps Issues Shareholder Letter And Provides Preliminary FY22 Financial Results And 2023 Guidance; Sees FY22 Revenue $405M-$415M Vs $444.2M Est; Announces $5M+ Share Repurchase Program; Expect To Grow Net Revenues At ~10%+ In 2023

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022   Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences

PROC